Dr. Daniel J. Jackson, M.D.
Pediatrics (Pediatric Allergy/Immunology Physician)
At a glance
- In the NPI registry since
- 2006
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Allergy/Immunology Physician primary
WI license 50473
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 4 companies reported 16 payments worth $38,499 in total to this clinician.
| GlaxoSmithKline, LLC. | $20,017 |
|---|---|
| Chiesi USA, Inc. | $8,475 |
| AstraZeneca Pharmaceuticals LP | $5,639 |
| Regeneron Pharmaceuticals, Inc. | $4,369 |
| Consulting Fee | $25,632 |
|---|---|
| Travel and Lodging | $12,616 |
| Food and Beverage | $250 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. Oct 17, 2025 | Travel and Lodging travel to London, Great Britain (UK) · in-kind | $11,547 |
| Chiesi USA, Inc. Apr 17, 2025 | Consulting Fee | $8,475 |
| GlaxoSmithKline, LLC. Nov 27, 2025 | Consulting Fee | $3,900 |
| Regeneron Pharmaceuticals, Inc. Jan 31, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $2,971 |
| AstraZeneca Pharmaceuticals LP Jun 18, 2025 | Consulting Fee TEZSPIRE · Respiratory | $2,954 |
| AstraZeneca Pharmaceuticals LP Dec 4, 2025 | Consulting Fee TEZSPIRE · Respiratory | $2,685 |
| GlaxoSmithKline, LLC. Mar 11, 2025 | Consulting Fee | $2,600 |
| Regeneron Pharmaceuticals, Inc. Jan 31, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $1,398 |
| GlaxoSmithKline, LLC. Apr 2, 2025 | Consulting Fee | $650 |
| GlaxoSmithKline, LLC. Oct 17, 2025 | Travel and Lodging travel to London, Great Britain (UK) · in-kind | $410 |
All 13 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Dec 4, 2025 | Consulting Fee TEZSPIRE · Respiratory | $2,685 |
| GlaxoSmithKline, LLC. Nov 27, 2025 | Consulting Fee | $3,900 |
| GlaxoSmithKline, LLC. Nov 27, 2025 | Travel and Lodging travel to SanDiego, CA | $50.00 |
| GlaxoSmithKline, LLC. Oct 17, 2025 | Travel and Lodging travel to London, Great Britain (UK) · in-kind | $11,547 |
| GlaxoSmithKline, LLC. Oct 17, 2025 | Travel and Lodging travel to London, Great Britain (UK) · in-kind | $410 |
| GlaxoSmithKline, LLC. Oct 17, 2025 | Travel and Lodging travel to London, Great Britain (UK) · in-kind | $382 |
| GlaxoSmithKline, LLC. Oct 17, 2025 | Travel and Lodging travel to London, Great Britain (UK) · in-kind | $227 |
| AstraZeneca Pharmaceuticals LP Jun 18, 2025 | Consulting Fee TEZSPIRE · Respiratory | $2,954 |
| Chiesi USA, Inc. Apr 17, 2025 | Consulting Fee | $8,475 |
| GlaxoSmithKline, LLC. Apr 2, 2025 | Consulting Fee | $650 |
| GlaxoSmithKline, LLC. Mar 11, 2025 | Consulting Fee | $2,600 |
| Regeneron Pharmaceuticals, Inc. Jan 31, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $2,971 |
| Regeneron Pharmaceuticals, Inc. Jan 31, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $1,398 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $2,977,729 in research payments for these studies, mostly to the institutions running them.
- Panda prevention of asthma exacerbations using dupilumab in urban children and adolescents
Regeneron Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.